801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsActive Pharmaceutical Ingredients

Ombitasvir Drug Active Ingredients CAS 1258226-87-7 High Purity Anti Hepatitis C

Ombitasvir Drug Active Ingredients CAS 1258226-87-7 High Purity Anti Hepatitis C

Ombitasvir Drug Active Ingredients CAS 1258226-87-7 High Purity Anti Hepatitis C

Product Details:

Place of Origin: China
Brand Name: Newlystar
Model Number: In - house

Payment & Shipping Terms:

Minimum Order Quantity: 10kg
Price: Negotiation
Packaging Details: Tin
Delivery Time: 30days
Payment Terms: L/C, T/T
Supply Ability: one ton per month
Contact Now
Detailed Product Description
Product: Ombitasvir API CAS NO.: 1258226-87-7
Purity: NLT 99.0% Standard: In - House
Usage: Anti Hepatitis C Virus

Ombitasvir Drug Active Ingredients CAS 1258226-87-7 High Purity Anti Hepatitis C

 

 

Ombitasvir API

CAS: 1258226-87-7

Purity: NLT 99.0%

 

Description :

Ombitasvir is a direct acting inhibitor of Nonstructural Protein 5A (NS5A) of Hepatitis C Virus (HCV) and is currently approved for use in combination with other antivirals for the treatment of chronic HCV infection. Despite lacking enzymatic activity, NS5A is necessary for viral replication and virion assembly through interaction with other nonstructural proteins. By combining ombitasvir with other antiretroviral medications into fixed dose products, the viral lifecycle can be targeted at multiple stages while simultaneously reducing the risk of developing resistant viral strains. Within Canada and the United States, Ombitasvir is currently available in three fixed dose products: Viekira Pak (FDA), Technivie (FDA and Health Canada), and Holkira Pak (Health Canada). When used within the fixed dose combination product of paritaprevir/ombitasvir/ritonavir (Technivie), ombitasvir is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis. When used within the fixed dose combination product of paritaprevir/ombitasvir/dasabuvir/ritonavir (Viekira Pak), ombitasvir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis.

 

Indication :

When used within the fixed dose combination product of paritaprevir/ombitasvir/ritonavir (Technivie), ombitasvir is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis. When used within the fixed dose combination product of paritaprevir/ombitasvir/dasabuvir/ritonavir (Viekira Pak), ombitasvir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Luke Liu

Send your inquiry directly to us (0 / 3000)